摘要 Introduction: In the management of upper tract urothelial cell carcinoma (UTUC) endoscopic, nephron sparing procedures like ureterorenoscopy (URS) or percutaneous tumour resection (PCTR) still play a very limited role. This could lead to possible unnecessary radical nephroureterectomies (RNU), still being the gold standard treatment. The risk of chronic kidney disease (CKD) later in life is important. In this study we present the results of 24-year experience with PCTR in a single institution. Methods: We identified 44 patients who underwent PCTR between 1992 and 2015. Radical resection was achieved in 40 patients who were included in this study. Demographic and clinical data, including tumour recurrence, progression to RNU, tumour grade and overall survival (OS) were retrospectively acquired. An outcome analysis was conducted. Results: Median age at diagnosis was 68 years (range 42e94 years). Low grade tumours were found in 37 patients (92.5%) and high grade tumours in three patients (7.5%). Median followup was 53 months during which 20 patients developed upper tract recurrences (50.0%). The longest time to recurrence was 97 months. At follow-up 11 patients (27.5%) underwent an RNU and two patients died from UTUC. RNU could be avoided in 29 patients (72.5%). In this study we found that multifocality is a significant risk factor for recurrence, but not for stage progression to RNU. Conclusion: PCTR is a surgically and oncologically safe procedure. Renal preservation in patients with UTUC who are eligible for percutaneous resection can be achieved in the majority of patients. Selection criteria for PCTR should be further refined, leading to a wider application of PCTR in the future. Follow-up needs invasive procedures and should be long term.
Abstract: Introduction: In the management of upper tract urothelial cell carcinoma (UTUC) endoscopic, nephron sparing procedures like ureterorenoscopy (URS) or percutaneous tumour resection (PCTR) still play a very limited role. This could lead to possible unnecessary radical nephroureterectomies (RNU), still being the gold standard treatment. The risk of chronic kidney disease (CKD) later in life is important. In this study we present the results of 24-year experience with PCTR in a single institution. Methods: We identified 44 patients who underwent PCTR between 1992 and 2015. Radical resection was achieved in 40 patients who were included in this study. Demographic and clinical data, including tumour recurrence, progression to RNU, tumour grade and overall survival (OS) were retrospectively acquired. An outcome analysis was conducted. Results: Median age at diagnosis was 68 years (range 42e94 years). Low grade tumours were found in 37 patients (92.5%) and high grade tumours in three patients (7.5%). Median followup was 53 months during which 20 patients developed upper tract recurrences (50.0%). The longest time to recurrence was 97 months. At follow-up 11 patients (27.5%) underwent an RNU and two patients died from UTUC. RNU could be avoided in 29 patients (72.5%). In this study we found that multifocality is a significant risk factor for recurrence, but not for stage progression to RNU. Conclusion: PCTR is a surgically and oncologically safe procedure. Renal preservation in patients with UTUC who are eligible for percutaneous resection can be achieved in the majority of patients. Selection criteria for PCTR should be further refined, leading to a wider application of PCTR in the future. Follow-up needs invasive procedures and should be long term.
Willem E. Strijbos, Bart van der Heij. Percutaneous resection of upper tract urothelial cell carcinoma: When, how, and is it safe?[J]. Asian Journal of Urology, 2016, 3(3): 134-141.
Willem E. Strijbos, Bart van der Heij. Percutaneous resection of upper tract urothelial cell carcinoma: When, how, and is it safe?. Asian Journal of Urology, 2016, 3(3): 134-141.
Rouprêt M, Babjuk M, Compérat E, Zigeuner R, Sylvester RJ, Burger M, et al. European guidelines on upper tract urothelial carcinomas: 2013 update. Eur Urol 2013;63:1059-71.
[4]
IKNL, Cancer Centre of the Netherlands. Dutch cancer figures, urinary tract 1990-2015. http://www.cijfersoverkanker.nl.
[5]
Margulis V, Shariat SF, Matin SF, Kamat AM, Zigeuner R, Kikuchi E, et al. Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration. Cancer 2009;115:1224-33.
[6]
Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risk of death, cardiovascular events and hospitalization. N Engl J Med 2004;351:1296-305.
[7]
Huang WC, Levey AS, Serio AM, Snyder M, Vickers AJ, Raj GV, et al. Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study. Lancet Oncol 2006;7:735-40.
[8]
Raman JD, Lin YK, Kaag M, Atkinson T, Crispen P, Wille M, et al. High rates of advanced disease, complication and decline of renal function after radical nephroureterectomy. Urol Oncol 2014;32:47.e9-14.
[9]
Cutress ML, Stewart GD, Zakikhani P, Phipps S, Thomas BG, Tolley DA. Ureteroscopic and percutaneous management of upper tract urothelial carcinoma (UTUC): systematic review. BJU Int 2012;110:614-28.
[10]
Motamedinia P, Keheila M, Leavitt DA, Rastinehad AR, Okeke Z, Smith AD. The expanded use of percutaneous resection for upper tract urothelial carcinoma: a 30-year comprehensive experience. J Endourol 2015;20:1-6.
[11]
Rouprêt M, Babjuk M, Compérat E, Zigeuner R, Sylvester RJ, Burger M, et al. European guidelines on urothelial carcinomas of the upper urinary tract. 2015. limited update march 2015.
[12]
Rouprêt M, Zigeuner R, Palou J, Boehle A, Kaasinen E, Sylvester R, et al. European guidelines for the diagnosis and management of upper tract urothelial cell carcinomas: 2011 update. Eur Urol 2011;59:584-94.
[13]
Plancke HR, Strijbos WE, Delaere KP. Percutaneous endoscopic treatment of urothelial tumours of the renal pelvis. Br J Urol 1995;75:736-9.
[14]
Palou J, Piovesan LF, Huguet J, Salvador J, Vicente J, Villavicencio H. Percutaneous nephroscopic management of upper tract transitional cell carcinoma: recurrence and long term follow-up. J Urol 2004;172:66-9.
[15]
Williams AK, Kassouf W, Chin J, Rendon R, Jacobsen N, Fairey A, et al. Multifocality rather than tumour location is a prognostic factor in upper tract urothelial carcinoma. Urol Oncol 2013;31:1164-5.
[16]
Yafi FA, Novara G, Shariat SF, Gupta A, Matsumoto K, Walton TJ, et al. Impact of tumour location versus multifocality in patients with upper tract urothelial carcinoma treated with nephroureterectomy and bladder cuff excision: a homogeneous series without perioperative chemotherapy. BJU Int 2012;110:E7-13.
[17]
Ouzzane A, Colin P, Xylinas E, Pignot G, Ariane MM, Saint F, et al. Ureteral and multifocal tumours have worse prognosis than renal pelvic tumours in urothelial carcinoma of the upper urinary tract treated by nephroureterectomy. Eur Urol 2011; 60:1258-65.
[18]
Rastinehad AR, Ost MC, Vanderbrink BA, Greenberg KL, El-Hakim A, Marcovich R, et al. A 20-year experience with percutaneous resection of upper tract transitional carcinoma: is there an oncologic benefit with adjuvant bacillus Calmette Guerin therapy? Urology 2009;73:27-31.
[19]
Hendin BN, Streem SB, Levin HS, Klein EA, Novick AC. Impact of diagnostic ureteroscopy on long term survival in patients with upper tract urothelial cell carcinoma. J Urol 1999;161:783-5.
[20]
Yakoubi R, Colin P, Seisen T, Léon P, Nison L, Bozzini G, et al. Radical nephroureterectomy versus endoscopic procedures for the treatment of localised upper tract urothelial carcinoma: a meta analysis and a systematic review of current evidence from comparative studies. Eur J Surg Oncol 2014;40: 1629-34.
[21]
Gadzinski AJ, Roberts WW, Faerber GJ, Wolf JS. Long term outcomes of nephroureterectomy versus endoscopic management for upper tract urothelial carcinoma. J Urol 2010; 183:2148-53.
Christopher Hartman, Nikhil Gupta, David Leavitt, David Hoenig, Zeph Okeke, Arthur Smith. Advances in percutaneous stone surgery[J]. Asian Journal of Urology, 2015, 2(1): 26
-32
.
